All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Vaccines aim to activate a specific immune response and various peptide/protein vaccines are currently under investigation for tumor treatment. Examples include peptides derived from myeloma-associated antigens, such as mutant Wilms tumor 1 (WT 1), X-box binding protein 1 (XBP1), syndecan-1 (CD138), and CS1 (CD319).